Formycon AG (ETR:FYB)
29.70
-0.80 (-2.62%)
Feb 21, 2025, 5:35 PM CET
Formycon AG Revenue
Formycon AG had revenue of 26.89M EUR in the half year ending June 30, 2024, with 52.42% growth. This brings the company's revenue in the last twelve months to 60.80M, down -11.42% year-over-year. In the year 2023, Formycon AG had annual revenue of 77.70M with 82.83% growth.
Revenue (ttm)
60.80M
Revenue Growth
-11.42%
P/S Ratio
8.13
Revenue / Employee
254.39K
Employees
238
Market Cap
524.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | 33.16M | -9.84M | -22.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 22.67B |
Merck KGaA | 20.96B |
Bayer Aktiengesellschaft | 46.74B |
Fresenius SE & Co. KGaA | 22.81B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.24B |
Carl Zeiss Meditec AG | 2.08B |
SCHOTT Pharma AG & Co. KGaA | 954.68M |
Formycon AG News
- 1 day ago - EQS-DD: Formycon AG: Dr. Andreas Seidl, buy - Wallstreet:Online
- 2 days ago - EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin - Wallstreet:Online
- 5 days ago - Formycon AG: Biosimilar Updates & Conference Call Invite - Wallstreet:Online
- 5 days ago - EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call - Wallstreet:Online
- 5 days ago - EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 - Wallstreet:Online
- 17 days ago - EQS-News: Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea biosimilar FYB203/AHZANTIVE in the Asia-Pacific Region - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names AHZANTIVE and Baiama - Wallstreet:Online
- 5 weeks ago - EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi (ustekinumab), a biosimilar to Stelara - Wallstreet:Online